[go: up one dir, main page]

CY1108610T1 - Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες - Google Patents

Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες

Info

Publication number
CY1108610T1
CY1108610T1 CY20081100848T CY081100848T CY1108610T1 CY 1108610 T1 CY1108610 T1 CY 1108610T1 CY 20081100848 T CY20081100848 T CY 20081100848T CY 081100848 T CY081100848 T CY 081100848T CY 1108610 T1 CY1108610 T1 CY 1108610T1
Authority
CY
Cyprus
Prior art keywords
derivatives
therapeutic agents
peptides
relates
present
Prior art date
Application number
CY20081100848T
Other languages
English (en)
Inventor
Jacques Theze
Ralph Eckenberg
Jean-Louis Moreau
Michel Goldberg
Thierry Rose
Pedro Alzari
Jean-Claude Mazie
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of CY1108610T1 publication Critical patent/CY1108610T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Συνθέσεις που έχουν δραστικότητα ομοιάζουσα με IL-2 και χρήση αυτών στη θεραπεία ή πρόληψη ανεπιθύμητων ανοσοαντιδράσεων, όπως απόρριψης μοσχεύματος ή αυτοάνοσων διαταραχών, για παράδειγμα ρευματοειδούς αρθρίτιδας. Αυτές οι συνθέσεις ορίζονται ως α) πεπτίδια από Ν-άκρο από IL-2 που αναστέλλουν ή μιμούνται τη σύνδεση έλικας Α της IL-2 προς μια υπομονάδα ενός IL-2R, διεγείροντας φωσφορυλίωση της υπομονάδας του IL-2R ή β) αντισώματα τα οποία αναγνωρίζουν το πεπτίδιο της εφεύρεσης και η θεραπευτική χρήση αυτών των αντισωμάτων.
CY20081100848T 1998-07-16 2008-08-12 Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες CY1108610T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/116,594 US6168785B1 (en) 1998-07-16 1998-07-16 Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
EP99936898A EP1097173B1 (en) 1998-07-16 1999-07-16 The use of peptides of il-2 and derivatives thereof as therapeutic agents

Publications (1)

Publication Number Publication Date
CY1108610T1 true CY1108610T1 (el) 2014-04-09

Family

ID=22368127

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100848T CY1108610T1 (el) 1998-07-16 2008-08-12 Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες

Country Status (11)

Country Link
US (4) US6168785B1 (el)
EP (1) EP1097173B1 (el)
AT (1) ATE396205T1 (el)
AU (1) AU5186799A (el)
CA (1) CA2337511A1 (el)
CY (1) CY1108610T1 (el)
DE (1) DE69938786D1 (el)
DK (1) DK1097173T3 (el)
ES (1) ES2308845T3 (el)
PT (1) PT1097173E (el)
WO (1) WO2000004048A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6929791B2 (en) 1998-07-16 2005-08-16 Institut Pasteur Peptides of IL-2 and derivatives thereof
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7662368B2 (en) * 1999-07-16 2010-02-16 Institut Pasteur Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
ATE401345T1 (de) * 2002-08-06 2008-08-15 Aplagen Gmbh Synthetische mimetika von physiologischen bindungsmolekülen
AU2003253381A1 (en) * 2002-08-06 2004-02-25 Aplagen Gmbh Binding molecules
KR101403910B1 (ko) 2003-11-04 2014-06-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법
AU2005280528B2 (en) * 2004-07-30 2010-12-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
AU2005289685B2 (en) 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9901731B2 (en) * 2006-01-31 2018-02-27 Medtronic, Inc. Medical electrical lead having improved inductance
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
EP3134132B1 (en) * 2014-04-22 2019-07-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
JP7407511B2 (ja) 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
AU2019274409B2 (en) 2018-05-21 2022-07-14 Nektar Therapeutics Selective Treg stimulator RUR20KD-IL-2 and related compositions
SG11202011460YA (en) 2018-06-25 2020-12-30 Univ Washington De novo design of potent and selective interleukin mimetics
US12234572B2 (en) 2018-11-20 2025-02-25 University Of Washington Split interleukin mimetics and their use
JP7303391B2 (ja) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド バイアス型ｉｌ２ムテイン、方法、および組成物
AU2022414070A1 (en) 2021-12-14 2024-05-16 Eli Lilly And Company Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091539B2 (en) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
WO1990000565A1 (en) * 1988-07-05 1990-01-25 Amgen Inc. Interleukin ii analogs
NZ234674A (en) 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
CU22222A1 (es) * 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents

Also Published As

Publication number Publication date
US6825334B1 (en) 2004-11-30
US7101965B2 (en) 2006-09-05
DK1097173T3 (da) 2008-09-01
ES2308845T3 (es) 2008-12-01
PT1097173E (pt) 2008-08-26
CA2337511A1 (en) 2000-01-27
US20040202661A1 (en) 2004-10-14
EP1097173A1 (en) 2001-05-09
DE69938786D1 (de) 2008-07-03
US6168785B1 (en) 2001-01-02
EP1097173B1 (en) 2008-05-21
US6596853B1 (en) 2003-07-22
ATE396205T1 (de) 2008-06-15
WO2000004048A1 (en) 2000-01-27
AU5186799A (en) 2000-02-07

Similar Documents

Publication Publication Date Title
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
ATE231872T1 (de) Thiazolopyrimidinderivate
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69907977D1 (de) Pyrrolobenzodiazepine
CY1106156T1 (el) Νεα χρηση βουδεσονιδης και φορμοτepολης
ATE233274T1 (de) Oxyiminopregnancarbolactone
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE210988T1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
IT1285770B1 (it) Composti corticoidei
ATE203519T1 (de) Chinolinderivate als antimalariamittel
SE9801494D0 (sv) Novel use
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
BR0316544A (pt) Compostos calcilìticos
ATE28188T1 (de) Antikonvulsive mittel.
NO20005548L (no) Mykobakterieinhibitorer
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
ATE57526T1 (de) P-acylaminobenzamide.
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
DE50004023D1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one